Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $87.83 | $0.00 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · derivative · entry 6 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2024-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
SaleCommon Stock | 80 | $219.31 | $17,545.11 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · nonDerivative · entry 5 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,221 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
SaleCommon Stock | 921 | $218.75 | $201,472.89 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · nonDerivative · entry 4 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,301 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
SaleCommon Stock | 514 | $217.29 | $111,684.59 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · nonDerivative · entry 3 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
SaleCommon Stock | 485 | $216.47 | $104,990.23 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · nonDerivative · entry 2 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:50 UTC |
WIENS HAROLD JDirector
|
Exercise / conversionCommon Stock | 2,000 | $87.83 | $175,660.00 |
DisclosureSEC source: 0000914190-19-000460 · edgar.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 21:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 100 | $222.62 | $22,262.36 |
DisclosureSEC source: 0000914190-19-000434 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,756 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.15 to $222.765, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 11,772 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000434 · edgar.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,818 Underlying: Common Stock · 11,772 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 11,772 | $222.12 | $2,614,814.30 |
DisclosureSEC source: 0000914190-19-000434 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,856 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.87, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 11,772 | $67.46 | $794,139.12 |
DisclosureSEC source: 0000914190-19-000434 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $60.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 8,347 | $219.33 | $1,830,730.82 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,374 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.0426 to $219.9846, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 5,000 | $61.46 | $307,300.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 10,000 | $60.46 | $604,600.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 23,651 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · derivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,651 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,600 | $216.16 | $345,850.24 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.01 to $216.20, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 22,051 | $215.55 | $4,753,051.15 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,907 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.00 to $215.9956, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 23,651 | $94.35 | $2,231,471.85 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 11,349 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · derivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,651 Underlying: Common Stock · 11,349 shares Expires 2021-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 11,349 | $215.36 | $2,444,131.99 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.00 to $215.84, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:25 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 11,349 | $94.35 | $1,070,778.15 |
DisclosureSEC source: 0000914190-19-000420 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Dec 17, 2019 21:32 UTC |
Furlow Brenda S.SVP - General Counsel
|
GiftCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,711 F1 · shares: Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC |
HIGGINS JOHN LDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000010 · edgar.xml · derivative · entry 12 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000010 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,021 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:06 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000016 · edgar.xml · derivative · entry 4 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:06 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000016 · edgar.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:05 UTC |
WIENS HAROLD JDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000015 · edgar.xml · derivative · entry 8 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:05 UTC |
WIENS HAROLD JDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000015 · edgar.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,221 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000013 · edgar.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000013 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,721 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:04 UTC |
Vessey RupertDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000014 · edgar.xml · derivative · entry 3 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:04 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000014 · edgar.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC |
Nusse RoelandDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000012 · edgar.xml · derivative · entry 12 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000012 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,721 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC |
Seth AlpnaDirector
|
GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000011 · edgar.xml · derivative · entry 4 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000011 · edgar.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:58 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000009 · edgar.xml · derivative · entry 10 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:58 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000009 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,221 Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:42 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
PurchaseCommon Stock | 100 | $185.00 | $18,500.00 |
DisclosureSEC source: 0000914190-19-000370 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Step-Daughter Disclosed balance after: 100 Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:42 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
PurchaseCommon Stock | 100 | $185.00 | $18,500.00 |
DisclosureSEC source: 0000914190-19-000370 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Step-Son Disclosed balance after: 100 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Exercise / conversionRestricted Stock Units · Derivative | 2,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · derivative · entry 6 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs. F3 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Tax withholdingCommon Stock | 900 | $197.57 | $177,813.00 |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Exercise / conversionCommon Stock | 2,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:33 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000330 · edgar.xml · derivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 4,925 performance RSUs. F3 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 4,925 performance RSUs. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:33 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 2,424 | $197.57 | $478,909.68 |
DisclosureSEC source: 0000914190-19-000330 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,883 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:33 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 4,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000330 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:33 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 24,979 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000329 · edgar.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 24,979 performance RSUs. F4 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 24,979 performance RSUs. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:33 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 24,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000329 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 1,759 performance RSUs. F3 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 1,759 performance RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.